From population health to personalised insight—Antidote Analytics is reshaping the future of clinical decision-making.
BMI misclassifies approximately 50% of patients, resulting in both unnecessary treatments and missed opportunities for early intervention. Liver fat—linked to conditions like NAFLD and NASH—remains significantly under-diagnosed, largely due to the reliance on costly tools such as MRI and FibroScan. At the same time, the NHS and global health systems are under growing financial pressure from rising rates of obesity, Type 2 diabetes, and fatty liver disease.
Our flagship offering, the Body Composition Index (BCI) brings accurate body composition analysis into everyday clinical practice—no scanner, no guesswork, just medically meaningful insight.
Antidote Analytics has developed a breakthrough AI-driven metric, BCI (Body Composition Index) — the first scalable replacement for BMI. BCI accurately predicts visceral, subcutaneous, and liver fat using easy-to-measure inputs, delivering clinically meaningful data with no scans, hardware, or behavioural input required.
This core technology has the potential to become the default health risk indicator across healthcare, insurance, pharma, and wellness — where BMI currently dominates but underperforms.
.
